Tetrahydroprotoberberine alkaloids have shown interesting polypharmacological actions at dopamine receptors and are a unique template from which to mine novel molecules with dual selective actions at D1 and D3 receptors. Such compounds will be valuable to evaluate as anti-cocaine therapeutics. Towards that eventual goal, we engaged an SAR study in which a series of C9 alkoxy analogues of the D1/D2/D3 ligand (-)-stepholidine that possessed or lacked a C12 bromo functionality, were synthesized and evaluated for affinity at dopamine D1, D2 and D3 receptors. We found that the analogues are generally selective for the D1 receptor. Small n-alkoxy substituents (up to 4 carbons in length) were generally well tolerated for high D1 affinity but such groups reduced D3 affinity. In the case of C12 brominated analogues, C9 alkoxylation also had little effect on D1 affinity for the smaller alkoxy groups, but reduced D2 and D3 affinities significantly. C12 bromination tends to increase D1 receptor selectivity. A number of compounds were identified that retain affinity for D1 and D3 receptors but lack D2 receptor affinity. Among them, compound 22a was found to be a selective D1/D3 dual antagonist (Ki ¼ 5.3 and 106 nM at D1 and D3 receptors). Docking studies performed on the analogues at the D3 receptor revealed a number of interactions that are important for affinity including a critical N -Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions between the aryl rings and Phe106 and Phe345. The analogues adopt an orientation in which ring A is located in the orthosteric binding site while the C9 alkoxy substituents attached to ring D project into the secondary binding pocket of the D3 receptor.
Introduction
The interesting central nervous system (CNS) receptor pharmacology exhibited by members of the tetrahydroprotoberberine (THPB) class of alkaloids, has led to a number of synthetic and biological explorations on the scaffold. Naturally occurring THPBs as well as synthetic derivatives have shown activity at D1 and D2 receptors and are promising lead compounds for the development of therapeutics to treat a range of neuropsychiatric disorders and drug abuse [1, 2] . For example, stepholidine (1, Fig. 1 ) displays a very rare D1 agonist/D2 antagonist/D3 antagonist profile and possesses antipsychotic, memory enhancing and anti-addiction properties [3e12] . Isocorypalmine (2) is a D1 partial agonist/D2 antagonist/D3 antagonist that has been shown to reduce cocaine reinstatement [13] . Tetrahydropalmatine (3) is a D1/D2 antagonist with potential as an anti-addiction therapeutic [13e20] . Govadine (4) has cognitive enhancement properties which have been attributed to antagonist activity at D1 and D2 receptors [21e24] . The synthetic THPB 12-chloroscoulerine (5) displays D1 agonist/D2 antagonist activity and potent antipsychotic properties [25e27] . Overall, it appears that the dopamine receptor polypharmacology of THPBs is relevant to their central nervous system (CNS) therapeutic potential.
A number of SAR studies have been performed on the THPB template previously which have indicated that the placement and identity of substituents on the aryl rings of THPBs can significantly influence affinity and activity of the compounds at dopamine D1 and D2 receptors [1,2,28e30] . We considered the possibility that the THPB scaffold could provide a source for novel compounds with potent polypharmacological activities at dopamine receptors. We are particularly interested in obtaining compounds that possess selective, dual D1/D3 activity (but lacking D2 affinity) as such compounds will be useful as tools to further probe the effects of multiple receptor modulation in the treatment of substance abuse disorders. As blockade of D2 receptors is associated with motoric side effects we envisage that selective dual D1/D3 agents will have a lower propensity to produce such side effects. In light of these promising outcomes, we engaged an SAR study as part of a longer term strategy to use THPBs to acquire new pharmacological tools and drugs relevant to substance abuse disorders. This report describes synthetic, biological and computational experiments in this direction.
Results and discussion

Synthesis
As alluded to before several THPBs (natural and synthetic) have been evaluated at D1 and D2 receptors and promising activities have been discovered for a number of compounds which therefore makes the THPB template a valuable and interesting subject of synthetic and medicinal chemistry studies. We chose stepholidine (1) as the lead compound for this study. Data from the Psychoactive Drug Screening Program (PDSP) indicates that 1 has affinity for D1, D2 and D3 receptors with K i values of 5.9, 974 and 30 nM respectively. Prior SAR work on stepholidine suggests an important role for the C2 and C10 phenolic groups for affinity at D1 and D2 receptors [2] . Indeed the phenolic groups of THPBs are generally recognized as being very important for affinity at D1 and D2 receptors and the placement of oxygenated groups on the template can impact D1/D2 selectivity as well. For example coreximine, an isomer of 1 that contains a C11 methoxy group rather than the C9 methoxy group of stepholidine, is selective for the D2 receptor (i.e in contrast to 1 which is D1 selective) [30] . Although some D1 and D2 receptor binding studies have been performed on THPBs in general and on stepholidine in particular, there have been no prior SAR studies investigating the tolerance for substituents at the C9 position of stepholidine with respect to D1 and D2 affinities.
Furthermore, there is a paucity of SAR information concerning the impact of structural modification of THPBs in general (including stepholidine) in relation to affinity and activity at D3 receptors [31] . Halogen atoms can provide significant gains in receptor affinity to a scaffold [32] . Although the presence of a C12 chloro group affords high D1 receptor affinity in the case of 12-chloroscoulerine (5), the effect of the presence of a bromo group at C12 of stepholidine analogues on D1, D2 and D3 affinity, has not been assessed up to now. Thus to illuminate these aspects of the SARs of THPBs in general and stepholidine in particular, we focused our study on the C9 and C12 positions.We targeted the preparation of a series of C9 alkoxy analogues as these compounds would help to elucidate the steric tolerance at this position for dopamine receptor affinities. The addition of a C12 bromine atom to the aforementioned compounds would reveal whether bromination at C12 may enhance dopamine receptor affinities and the extent to which this was generalizable for parallel series of compounds. We envisaged that the synthesis of the C9 alkoxy/C12 bromo analogues could be effected via a brominated 1,2,4,5-tetrasubstituted phenylacetic acid intermediate (13, Scheme 1) . This intermediate would eventually be transformed into the ring D moiety in the analogues [33] . Removal of the bromo group from the C9 alkoxy/C12 bromo analogues would afford the desired, analogous C9 alkoxy compounds.
Preparation of the tetrasubstituted intermediate (13) commenced with 3,4-dihydroxybenzaldehyde (6) as shown in Scheme 1. Selective benzylation of the 4-hydroxyl group of 6 gave aldehyde 7. The phenolic group of 7 was then protected to give silyl ether 8. This was followed by bromination to afford aldehyde 9, which was then reduced to give alcohol 10. Compound 10 was converted to the dibromide 11 by reaction with PBr 3 . The primary bromide group of 11 was displaced by cyanide ion and the resulting nitrile (12) was hydrolyzed under basic conditions (resulting in concomitant removal of the silyl protecting group) to give acid 13.
Scheme 2 shows the preparation of the THPB framework and subsequent functionalization to afford the two series of analogues (the brominated series, 20aeg and the non-brominated series, 22aeg). Thus, acid 13 was coupled with readily available amine 14 and the amide 15 thus formed was cyclized under BischlerNapieralski conditions to give 16. The dihydroisoquinoline 16 was reduced via Noyori's method providing the benzyltetrahydroisoquinoline 17. Compound 17 was heated with formalin promoting Mannich cyclization to form the tetracyclic THPB skeleton in 18. Alkylation of the C9 phenolic group of 18 gave the C12 bromo/ C9 alkoxy intermediates 19aeg. The benzyl groups of the intermediates 19aeg were subsequently removed by treatment with concentrated HCl to give brominated analogues 20aeg. The corresponding C9 alkoxy analogues (22aeg) were prepared from 19aeg by treatment with i-PrMgCl (to remove the bromo group; compounds 21aeg), followed by treatment with concentrated HCl to effect debenzylation as before.
Biological evaluations
Binding affinity at D1, D2 and D3 receptors
Compounds 20ae20g and 22ae22g were assayed for binding affinity to human dopamine D1, D2 and D3 receptors by the Psychoactive Drug Screening Program (PDSP). Details of the screening protocol may be found online at the PDSP website (https://pdspdb. unc.edu/pdspWeb/). In brief, the compounds were initially assayed in quadruplicate at a 10 mM concentration at D1, D2, and D3 receptors. Compounds that showed an inhibition of binding of >50% were progressed to secondary assays to measure K i . The K i determinations were performed via 12-point concentrationresponse curves in triplicate (unless noted otherwise). This data is presented in Table 1. 2.2.1.1. SAR at the D1 receptor. At the D1 receptor, small C9 alkoxy groups were tolerated in the 20ae20g series of compounds. In fact, the C9 ethoxy (20a), n-propyloxy (20b) and n-butyloxy (20c) compounds had the highest D1 receptor affinities of all compounds evaluated (K i values of 1.3, 2.2 and 2.3 nM respectively). The methoxyethyl derivative 20g also had strong D1 receptor affinity (4.2 nM). When compared to 20c (which bears a similar length of atoms), this result tends to suggest that lipophilicity of the C9 substituent group per se is not a major contributor to affinity; perhaps steric effects are the major factors here. Alternatively, the Scheme 1. Reagents and conditions: (a) K 2 CO 3 , ACN, reflux, 2 h, 75%; (b) TEA, DMAP, TBDPSCl, DCM, 10 h; (c) Br 2 , MeOH, 1 h, 85% from 7; (d) NaBH 4 , MeOH, 1 h, 93%; (e) PBr 3 , DCM, 2 h, 82%; (f) NaCN, DMF, 3h, 75%; (g) NaOH, EtOH, H 2 O, 75 C, 5h, 81%. Scheme 2. Reagents and conditions: (a) EDC, DMF, 13, 12 h, 43%; (b) POCl 3 , ACN, 70 C, 1 h; (c) Noyori catalyst, DMF, HCOOH/TEA (5/2), 12 h, 40% from 15; (d) formalin, MeOH, 90 C, 3 h, 63%; (e) appropriate alkyl halide, K 2 CO 3 , DMF, 2e4 h, 64e82%; (f) conc. HCl, EtOH, 70 C, 1.5e2 h, 58e81%.for 20aeg; (g) i-PrMgCl, LiCl, THF, 0 C, 2 h. additional oxygen atom in the alkyl chain of 20g may be making significant H-bond contacts to overcome desolvation penalties upon binding to the receptor. The n-pentyloxy and n-hexyloxy analogues (20d and 20e respectively) showed diminished D1 receptor affinities as compared to the smaller homologues. The secbutyloxy analogue 20f (a mixture of diastereomers) also displayed strong D1 receptor affinity (9.7 nM). Thus branching in the pendant alkyl chain does not seem to negatively impact D1 receptor affinity in a major way.
In the case of the 22ae22g series of analogues, a similar trend as that obtained for the 20ae20g series was observed wherein the analogues with smaller n-alkoxy groups (22ae22c) and the methoxyethyl analogue (22g) showed the highest D1 affinity in the series. The 22ae22c subset of compounds, when compared to their C12 bromo counterparts (20ae20c), showed slightly diminished D1 receptor affinities (approximately 4e5 fold). The C9 sec-butyloxy analogue also showed reduced affinity (i.e. 22f versus 20f; approximately 7-fold). However, the affinities of the larger n-homologues (22d and 22e) and the methoxyethyl analogue (22g) was similar to that of the corresponding C12 bromo analogues.
A recent study has noted the importance of the C9 oxygenated substituent in THPBs wherein a hydroxyl group at C9 engendered higher D1 and D2 receptor affinities than isomers in which the hydroxyl group is positioned at C11 instead [28, 34] . Also, the presence of a C11 methoxyl group afforded higher dopamine receptor affinities than the comparable C11 hydroxy analogues. Thus, the position of phenolic and methoxyl groups in ring D can be very critical for D1 and D2 receptor affinities.
2.2.1.2. SAR at the D2 receptor. For the brominated series of compounds at the D2 receptor, there was a decrease in affinity as the length of the n-alkoxyl chain was extended from 3 to 6 carbon atoms (i.e. compounds 20be20e). Compounds 20a and 20g did not show any appreciable D2 receptor affinity in the primary assay and were not evaluated in the secondary assay. The affinities of the brominated group of compounds for the D2 receptor was significantly lower (>10-fold) than that for the D1 receptor for all compounds tested.
No clear trend could be discerned for the 22ae22g set of compounds at the D2 receptor and some compounds lacked any appreciable affinity from the primary assay (specifically 22a, 22c and 22e). Compound 22g when compared with butyloxy analogue 22c, showed improved D2 receptor affinity which suggests that the additional oxygen atom in 22g makes important binding contacts with the D2 receptor. This was a reversal in the trend that was observed with comparable compounds in the brominated series (i.e. compound 20c e 107 nM versus compound 20g e no activity). In general, the D2 receptor affinities for this group was lower than their D1 receptor affinities. Our work demonstrates that a 9-alkoxy, 10-hydroxy substitution pattern in ring D tends to favor selectivity for the D1 receptor and depending on the particular C9 alkoxy substituent, may decimate D2 receptor affinity.
2.2.1.3. SAR at the D3 receptor. At the D3 receptor, no clear trend was seen for either the brominated or non-brominated series of compounds. For the brominated group, most compounds (save for 20a) had lower affinity for the D3 receptor as compared to D2 and D1 receptors. Methoxyethyl analogue 22g had a 4-fold higher affinity than the n-butyloxy analogue 22c, indicating that perhaps the extra oxygen atom in 22g makes favorable D3 receptor contacts. All compounds assessed showed decreased D3 receptor affinity as compared to the lead compound stepholidine, except for compound 22g which showed similar D3 receptor affinity. In general, the absence of a C12 bromo group improves D3 receptor affinity (e.g. compare 22g versus 20g; 31 nM versus 726 nM respectively).
Evaluation of functional activity
We were pleased to find that a number of compounds displayed the extremely unusual binding profile that we desired, in that they had affinity for D1 and D3 receptors but lacked affinity for D2 receptors. Since compound 22a had the highest D3 affinity among all such compounds, we decided to further characterize the functional activity of this compound at D1 and D3 receptors as a representative of the series. In these assays compound 22a lacked intrinsic activity at D1 and D3 receptors (as measured by its inability to stimulate binding of GTPg-S as opposed to the activation caused by dopamine), indicating that the compound is not an agonist at either receptor. A follow-up D1 Tango antagonist assay at the PDSP revealed that 22a is in fact a D1 antagonist (IC 50 ¼ 416 nM; IC 50 of the standard SCH 23390 at D1 in this assay was 2.4 nM). Compound 22a is a dopamine D3 antagonist; it caused a dextral shift in the curve for dopamine in stimulating GTPg-S binding to cells heterologously expressing the D3 receptor with a K e of 3.15 nM.
D3 receptor docking studies
The analogues evaluated in this study generally exhibit high affinity and selectivity for the D1 receptor with low to moderate D3 affinity. As we were interested in obtaining compounds with high D3 affinity, we decided to dock the analogues at the D3 receptor as this could provide important revelations as to the receptor-ligand interactions that impact D3 affinity and thus facilitate future pharmacodynamic optimization. For these docking simulations, we prepared a target structure for the D3 receptor based on the X-ray crystal structure with PDB code 3PBL and resolution 2.89 Å [35] . The 3PBL receptor structure was obtained from the Protein Data Bank (www.rcsb.org) [36] and prepared for the modeling simulations by application of the Protein Preparation Wizard [37] in Maestro, which involves structure preprocessing and refinement stages. The former stage involves using Prime to add hydrogen atoms, generate disulfide bonds and complete missing side-chains. The structure refinement stage comprises removing water molecules, optimizing the hydrogen bonding network by rotating hydroxyl (and thiol) group orientations, producing appropriate tautomeric states of His residues and conducting chi flips of Asn, Gln and His residues. Finally, a restrained minimization is performed to relax the structure by relieving any strain and modifying heavy atom and hydrogen atom positions. The series of C9 analogues was docked into the pre-prepared D3 receptor binding pocket using Glide in 'Standard Precision' (SP) mode [38] . This process involved initially generating a receptor grid using an automated protocol in Maestro in which default settings were utilized for the grid parameters. A 10 Å cubic box was specified around the D3 receptor co-crystallized ligand and the analogue compounds were docked within the box. The docking procedure comprised the generation of ligand conformations, which are assessed in terms of the 'fit' of the ligand to the binding cavity and the complementarity of the protein-ligand interactions. This process allows poor scoring poses to be filtered out and those that successfully pass the screening are subsequently minimized using the OPLS_2005 force field [39] . For each C9 analogue, several poses pass the screening process and are minimized. In the final step, these minimized poses are rescored and ranked according to the Glidescore scoring function, which gives an estimate of the binding affinity. The Glidescore of the highest ranked pose for each ligand is shown in Table 2 . Overall, the non-brominated C9 analogues were found to have slightly lower Glidescore binding affinity values than the corresponding brominated ligands in agreement with the affinity measurements for these systems.
The non-brominated analogue 22g showed the highest D3 receptor affinity and to provide further insight into the key interactions in the complex, a representation of the binding pose for 22g and the corresponding brominated analogue 20g within the D3 receptor binding cavity are shown in Fig. 2 . The structures depicted represent the top-ranked binding modes for each ligand according to Glidescore. The poses for both ligands illustrate the important receptor-ligand interactions for these systems, including the critical quaternary N e Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions to Phe106 and Phe345 (Fig. 2a) . Furthermore, the non-brominated analogue makes an Hbond to Thr369 via the methoxyethyl substituent, whereas the bromine atom of the brominated system makes an additional interaction with the backbone of Ile183. The aromatic groups of the ligands project into the hydrophobic regions of the receptor binding site as illustrated in Fig. 2b . The Glidescore estimates of the binding energy for the two compounds are very similar, À8.0 and À7.8 kcal/mol for 22g and 20g, respectively. Overall, the nonbrominated ligand 22g is calculated to have a slightly higher lipophilic interaction energy, whereas the brominated compound 20g has a slightly better H-bonding energy. Qualitatively, these results match the experimentally observed affinities, however, at the quantitative level, the Glidescore values are too close to clearly differentiate the compounds.
The Glidescore outcomes for the C9 alkoxy substituents do not show significant differences as the length of the alkyl chain is increased. For instance, as the C9 alkoxy chain is lengthened from the ethyl to the n-hexyl chain (compounds 22aee), the estimated binding energy changes from À7.9 to À8.1 kcal/mol for the nonbrominated ligands. The non-brominated C9 sec-butyloxy analogue 22f also displayed a similar Glidescore energy of À7.8 kcal/mol. These values are all very close to that determined for the lead compound stepholoidine (À7.9 kcal/mol). The experimentally observed affinity values for the non-brominated C9 analogues also showed relatively little variation ranging from 106 to 195 nM with no particular trend as the size of the chain increases, except for the branched sec-butyloxy analogue 22f and the npentyloxy compound 22d, which were measured to have significantly lower affinity values of 450 and 3213 nM, respectively. The calculated Glidescore energies did not display these two outliers. In agreement with the experimental data, the corresponding brominated analogues (compounds 20aee) were found to have lower magnitude Glidescore values from À7.1 to À7.6 kcal/mol with the branched sec-butyloxy ligand 20f having a value of À7.7 kcal/mol. Again, in quantitative terms, there is no discernible trend in binding affinity values as the length of the chain increases or in terms of the chain branching. The n-butyloxy analogue 20c displayed the lowest experimentally observed affinity as well as the lowest Glidescore value, whereas compounds 20d, 20e and 20f with measured affinities greater than 2000 nM had similar Glidescore values to 20a and 20b, which had about 10-fold better observed affinities.
The binding poses for the ethoxy and n-hexyloxy C9 analogues with and without the bromine substituent within the D3 receptor binding pocket are depicted in Fig. 3 . These complexes involve the same key receptor-ligand interactions as discussed above, the quaternary N e Asp110 salt bridge, H-bonds to Ser192 and Cys181 and hydrophobic interactions to Phe106 and Phe345. The brominated analogues make an additional weak halogen bond [32] to the Ile183 backbone, however, this is more than balanced by the higher lipophilic interaction energies of the non-brominated systems. Examination of the D3 receptor binding site shows that the alkoxy groups of the C9 analogues, including the longest n-hexyloxy chain, project into the hydrophobic extracellular region of the binding cavity (the secondary binding pocket, SBP), without causing significant clashes with the receptor structure (Fig. 4) . The small variation in predicted binding energies according to Glidescore for these systems is, therefore, not surprising, although this does not explain the much larger differences in their measured affinity values. Nevertheless, overall in qualitative terms, the small decrease in the Glidescore binding energy for the brominated compared to the non-brominated compounds is in agreement with the decreased experimental affinity measurements for these ligands.
The behavior of both brominated and non-brominated C9 analogues were analyzed within the D3 binding site through molecular dynamics simulations. Six representative analogues were selected,
These six analogues were simulated within the AMBER molecular dynamics program for 100 ns simulation time in isochoric-isothermal conditions. The starting configuration for these six simulations consisted of the docked poses generated above, solvated in 10 Å a box of tip4pew water [42] . Protein atoms were parameterized with Amber14SB [43] , ligand parameters were assigned using the general amber force field (gaff) [44] . These configurations were minimized using 20000 steps steepest descent, heated to 300 K over the course of 240 ps in isochoric-isothermal conditions, and equilibrated for 20 ns in isobaric-isothermal conditions. During the production simulation protein heavy atoms were restrained with restraint weights of 2.5 kcal/Å 2 . The SHAKE algorithm was utilized to maintain hydrogen bond distances, Berendsen barostat to maintain constant pressure, and Langevin thermostat to maintain constant temperatures.
To assess the stability of these six analogues we evaluated two metrics: ligand root mean square deviation compared to their docked poses and ligand distance to the key aspartate (residue 110) throughout the 100 ns production simulation. These six analogues displayed low RMSD's that did not fluctuate significantly over our production simulation (Fig. 5) . The highest RMSD found between all six ligands was 1.9 Å by 22e, an n-hexyloxy analogue. The distance between each analogue center of mass and Asp 110 was evaluated to determine whether this key salt bridge contact is maintained. All six analogues displayed extremely stable distances to Asp 110 (Fig. 6 ). These quantities indicate that during this 100 ns simulation no ligands left the pocket, all ligands maintained the key aspartate salt bridge, and remained similar to the starting docked pose. [40, 41] involving the Br atom is given by the purple dashed line. b) Molecular surface of the binding cavity with the docked ligands 20g and 22g. The surface is color coded according to the electrostatic potential, with red denoting positive hydrophilic, blue denoting negative hydrophilic, and green representing hydrophobic regions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Conclusions
This is the first study that investigates the effects of alkoxy substitutions at the C9 position (alone or in tandem with C12 bromination) of (-)-stepholidine on affinity at D1, D2 and D3 receptors. In general, C9 alkoxy substituents impart D1 selectivity to the scaffold. C12 bromination has opposite effects on D1 and D3 affinities e C12 bromination tends to increase D1 affinity (particularly for small substituent groups) but reduces D3 affinity. C9 alkoxylation reduces D3 affinity, except in the case of compound 22g. Some C9 alkoxy compounds lacked affinity for the D2 receptor but it is still not clear how steric or electronic factors account for the lack of D2 receptor affinity. Compound 22a was found to be a dual D1/D3 receptor antagonist e thus it appears that extension of the C9 alkoxy chain of (-)-stepholidine reverses D1 functional activity.
In comparison to the experimentally measured ligand affinities, the Glidescore estimated binding energies from the D3 receptor docking simulations show some similarities and differences. This is perhaps unsurprising, as empirical scoring functions, such as Glidescore used in this work, typically work well in qualitatively distinguishing active from inactive ligands, however, they are often less successful at quantitatively rank ordering docked poses according to the scoring function values. Further aspects of the current work that probably prevented a definitive association between the docking scores and experimentally measured affinities include the small number of ligands studied in the biological assays and the docking simulations, the small observed affinity range for some of the ligands and the generation of multiple binding modes for each ligand in the receptor binding cavity. More extended studies comprising a larger and more diverse series of ligands would be needed to afford deeper insight and quantitative assessment of the performance of our ligand docking process. Nevertheless, despite these features, the in silico docking model was capable of successfully distinguishing between the brominated and non-brominated C9 analogues and allowed for the recognition of key proteinligand interactions within the D3 receptor binding pocket that need to be retained in the exploration of diverse and selective ligands with high affinity.
Modifications at C9 may be a means to generate dual potent selective D1/D3 ligands, but will be challenging especially with regards to obtaining high D3 receptor affinity. Further SAR and computational work on the scaffold is necessary to fulfill this goal. In order to provide deeper insight into the ligand requirements for D1/D3 selectivity, we have initiated docking studies into binding pockets of D1 and D2 receptor structures derived from homology models in comparison to D3. This is a large scale project that will form the central theme of a future publication. Our work demonstrates that a C-9 alkoxy, C10-hydroxy substitution pattern in ring D delivers selective D1 ligands and has uncovered novel and unique D1/D3 selective ligands that are useful leads for further optimization.
Experimental
General experimental procedures: All moisture-sensitive and oxygen-sensitive reactions were carried out in flame-dried glassware under a nitrogen atmosphere. Solvents and all other reagents were purchased at the highest commercial quality from Aldrich and Fisher Scientific USA and used without further purification. Anhydrous sodium sulfate was used as drying agent for work-up of reactions. HRESIMS spectra were obtained using an Agilent 6520 QTOF instrument. 1 . TLC plates were visualized by UV (254 nm) and by staining in an iodine chamber. Flash column chromatography was performed with silica gel 60 (EMD Chemicals, 230e400 mesh, 0.063 mm particle size).
4-benzyloxy-3-hydroxybenzaldehyde (7):
To a stirring solution of 3,4-dihydroxybenzaldehyde, 6 (25.0 g, 181.0 mmol) in anhydrous acetonitrile (300 mL), was added K 2 CO 3 (25.0 g, 181.0 mmol) followed by benzyl bromide (34.4 mL, 289.6 mmol) slowly, at room temperature, under an inert (N 2 ) atmosphere. The resulting reaction was heated to reflux and stirring was continued for 2 h. The reaction solvent was removed by evaporation under reduced pressure and to the resulting residue was added cold 10% NaOH solution and stirred for 10 min, after which ethyl acetate (100 mL) was added. The resulting biphasic mixture was separated and the aqueous layer was acidified with 4 N HCl and extracted with DCM (3 Â 300 mL). The combined organic layer was washed with brine solution, water, dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by crystallization using ethyl acetate to afford 7 (31.0 g, 75%). 1 85 mmol) in methanol (300 mL) was added bromine (2.19 mL, 42.85 mmol) slowly, at 0 C, under N 2 . The reaction mixture was allowed to attain room temperature and stirring was continued for 2 h. The solvent was removed by evaporation under reduced pressure and the resulting residue was dissolved in ethyl acetate (250 mL) and washed consecutively with brine solution and water. The organic layer was dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 10:90 and 12:88, EtOAC:Hexanes as eluent to afford compound 9 (20.0 g, 85%). 1 43 .99 mmol) in portion wise, at 0 C, under N 2 . The reaction mixture was allowed to come to room temperature and stirring was continued for 1 h. Thereafter the reaction was quenched with methanol. The solvent was removed by evaporation under reduced pressure and the resulting residue was dissolved in ethyl acetate (250 mL) and washed consecutively with brine and water. The organic layer was dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 20:80 EtOAC:Hexanes as eluent to afford compound 10 (18.7 g, 93%). 1 18 .58 mmol) slowly, at 0 C, under N 2 . The reaction mixture was allowed to stir at room temperature for 2 h. Then the reaction mixture was quenched with aqueous NaHCO 3 solution. The organic layer was separated and washed consecutively with brine solution and water. The organic layer was dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 12:88, EtOAC:Hexanes as eluent to afford compound, 9 (17.0 g, 82% 
2-(4-(benzyloxy)-2-bromo-5-hydroxyphenyl)acetic acid (13):
To a stirred solution of compound, 12 (12.5 g, 22.45 mmol) in a mixture of ethanol (65 mL) and water (65 mL) was added NaOH (2.69 g, 67.37 mmol), at room temperature. The resulting reaction mixture was heated at 75 C for 3 h, then another portion of NaOH (1.79 g, 44.91 mmol) was added to the reaction mixture and stirring was continued for another 2 h. The solvent was removed by evaporation under reduced pressure and the resulting residue was dissolved in water (150 mL) and washed with ethyl acetate. The aqueous layer was cooled to 0 C, and acidified (pH~2) with 3 N HCl. During the acidification product was precipitated out, which was filtered and dried under vacuum to afford 13 (6.14 g, 81% 
2-(4-(benzyloxy)-2-bromo-5-hydroxyphenyl)-N-(4-(benzyloxy)-3-methoxyphenethyl)acetamide (15):
To a mixture of 13 (5.0 g, 14.88 mmol), and amine 14 (3.82 g, 14.88 mmol) in anhydrous DMF (75 mL) was added EDCI (3.12 g, 16.36 mmol) followed by TEA (1.86 mL, 13.39 mmol), at 0 C. The resulting reaction mixture was warmed to room temperature and stirring was continued for overnight. The solvent was removed by evaporation under reduced pressure and the resulting residue was dissolved in ethyl acetate (100 mL) and washed with brine solution and water. The organic layer was dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound, 15 (3.80 g, 43% 75 g, 6 .52 mmol) in anhydrous acetonitrile (40 mL) was added POCl 3 (3.0 mL, 32.60 mmol), at room temperature, under N 2 . The resulting reaction was heated at 80 C for 2 h. Then solvent was removed by evaporation under reduced pressure and the resulting residue was quenched with cold saturated NaHCO 3 solution and extracted with ethyl acetate (3 Â 100 mL). The combined organic layer was washed with brine solution and water, dried over Na 2 SO 4 , and concentrated to obtain a residue, 16 (crude 3.60 g) which was utilized for the next step without further purification.
(S)-2-(benzyloxy)-5-[(7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-4-bromophenol (17): The imine 16 (3.60 g, 6.46 mmol) was dissolved in anhydrous DMF (20 mL), and the solution purged with nitrogen for 10 min. Then RuCl[(R,R)-TsDPEN(P-cymene)] (41.0 mg, 0.06 mmol) was added and purging was continued for a further 5 min. Thereafter a mixture of formic acid (1.36 mL, 36.19 mmol) and triethylamine (0.53 mL, 3.87 mmol) (v/v ¼ 5/2) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was adjusted to pH 8 with saturated NaHCO 3 and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na 2 SO 4 , and concentrated. The crude product was purified by column chromatography on silica gel using 3:97 to 5:95 MeOH:DCM as eluent to afford compound 17 (1.45 g, 40% over two steps). (18): To a stirred solution of compound 17 (1.0 g, 1.78 mmol) in anhydrous methanol (8.0 mL) was added formalin (7.0 mL), at room temperature. The resulting reaction mixture was heated at reflux temperature for 4 h. Then solvent was removed by evaporation under reduced pressure and the resulting residue was dissolved in ethyl acetate (50 mL) and washed with brine solution and water. The organic layer was dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound, 18 (0.64 g, 63% General synthetic procedure for the compounds 19a-19g as demonstrated for 19a: Compound, 18 (1.0 eq) was dissolved in anhydrous DMF, cooled to 0 C and K 2 CO 3 (2.0 eq) was added, followed by ethyl bromide (1.2 eq). The resulting reaction was allowed to reach ambient temperature and stirring was continued for 2e5 h. The reaction was quenched with cold water and extracted with ethyl acetate (3 Â 100 mL). The combined organic layer was washed with brine solution and water, dried over Na 2 SO 4 , and concentrated to obtain a residue which was purified by column chromatography on silica gel using 25:75 to 50:50 EtOAC:Hexanes as eluent to afford compound 19a as light yellow sticky solid.
((S)-2,10-bis(benzyloxy)-12-bromo-9-ethoxy-3-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino [ General synthetic procedure for the compounds 20ae20g as demonstrated for 20a: To a stirred solution of compound 19a (34 mg) in ethanol (4 mL) was added conc. HCl (1 mL), at room temperature. The resulting reaction mixture was refluxed for 2 h. Then the solvent was removed by evaporation under reduced pressure and the resulting residue was basified using aqueous ammonia solution and extracted with ethyl acetate (10 mL Â 2). The combined organic layer was washed with brine solution and water, dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound 20a as an off-white amorphous solid.
((S)-12-bromo-9-ethoxy-3-methoxy-5, General synthetic procedure for the compounds 22ae22g as demonstrated for 22a: To a stirred solution of compound, 19a (1.0 eq) in anhydrous THF (8.0 mL) was added i-PrMgCl.LiCl (2.0 eq mL), at room temperature. The resulting reaction mixture was allowed to stir for 4e8 h. After completion of the reaction, the reaction was quenched with water and extracted with ethyl acetate (50 mL). The combined organic layer was washed with brine solution and water, dried over Na 2 SO 4 , and concentrated under reduced pressure. Without further purification the residue (containing compound 21a) was subjected to the debenzylation procedure as shown for compound 20a to obtain compound 22a which was purified by column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound, 22a as a light yellow gum.
((S)-9-ethoxy-3-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-diol) (22a): Yield: 67% (18 mg from 42 mg of 19a), off-white gum; R f ¼ 0. 38 
